On Jan. 06, Perfetti Riccardo divested U.S. $383,711 in shares of Applied Therapeutics Inc.. The Chief Medical Officer sold 16,515 shares at a price per share of $23.23. The transaction decreased this specific insider’s holdings to 0 shares worth around $0.0 at present.
Truist launched its Applied Therapeutics Inc. [APLT] rating to the equivalent of a Buy and assigned the price target of $85, in a research note dated October 08, 2020. That figure represents around a 72.88% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with Truist’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in early October. Meanwhile, Goldman had launched its coverage on APLT with “Buy”, in a research note produced for clients April 22, 2020. In addition, there was a new coverage from Barclays on February 27, 2020. The research firm rated APLT “an Overweight”.
Is Applied Therapeutics Inc. [NASDAQ:APLT] a Good Buy Right Now?
It should be noted that APLT technical indicators for short, intermediate as well as long term progress have placed an overall average of 8% as Sell. The average signal changed from 40% Sell in the last week and compares with 72% Sell in the past month. Data from Applied Therapeutics Inc.’s Trend Spotter indicated that the signals were Strengthening. The stock current average is 0.13 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 0.16 million shares while the medium term average advocated for 50% Sell. The average long-term signal stands at 50% Sell and the 100-day average volume stands at 0.14 million shares.
APLT Price Performance
On Wall Street, Applied Therapeutics Inc. [NASDAQ:APLT] finished Friday’s session up 6.27% at $23.05. The stock went up to $23.46 at the same session while its lowest single day price was $21.31. In the last five days, it saw a rise of about 4.73%, Applied Therapeutics Inc. shares gained by almost 4.73% since the beginning of the year. However, the share price has dropped to as low as -59.84% below its one year high. On 01/06/21, the company shares recorded $23.92, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $21.30. The company’s shares have declined by -47.77% in the past year. The 50-day SMA achieved is $20.44 while the 200-day SMA is $29.37. Volume gained to 99541.0 from 69100.0 in the previous session.
APLT Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 21.75 level, and in case of violation of this particular level, it will cause more drop to 20.46 level. On the upper level, 24.76 is still the key resistance. The stock may increase to the subsequent resistance at 23.90. The Relative Strength Index (RSI) pinned on the 14-day chart is 55.29, implying a neutral technical stance while the MACD stands at -0.15, meaning price will decrease in the next trading period. Percent R indicator moved to 38.67%, implying low price movement. Stochastic %K at 44.01% suggest holding the stock.
What is the short interest in Applied Therapeutics Inc.?
Short interest in the Applied Therapeutics Inc. stock has surged, increasing by 0.13 million shares to total 1.57 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 1.7 million, data from Yahoo Finance shows. The decrease of -8.28% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 11.41% of the overall float for the stock.
Applied Therapeutics Inc.’s Biggest Shareholders: Who Owns Applied Therapeutics Inc. [APLT]?
Filings by Fidelity Management & Research Co showed that the firm now holds a total of 2,334,417 shares or roughly 10.38% of the outstanding APLT shares. This means their shares have increased by 378,248 from the 2,334,417 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, OrbiMed Advisors LLC updated stake is worth $35,821,271. Details in the latest 13F filings reveal that Rock Springs Capital Management L disposed off their 0.00% stake valued at $22,964,831 while Knoll Capital Management LP added theirs at $17,022,137. During the last quarter, Rock Springs Capital Management L liquidated 0 of its shares in Applied Therapeutics Inc. while Knoll Capital Management LP bought 84,742 shares. The BlackRock Fund Advisors’s holdings currently number 731,682 shares at $16865270.1. According to the firm’s last 13F report, The Vanguard Group, Inc. shares in the company at filing stood at 639,596 shares, roughly $14,813,043.
What are analyst thoughts on Applied Therapeutics Inc.?
Looking forward to the Applied Therapeutics Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Applied Therapeutics Inc. stock at $46.00 within the next 12 months, which represents almost 49.89 per cent growth from its previous closing price of $23.05. The highest analysts’ target for Applied Therapeutics Inc. stock projections is $85.00 and the lowest one is $35.00. Still, 7 analysts sharing their consensus rating for APLT stock in 2021 agree that it is a Buy.